Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02887443
Other study ID # SNT-I-017
Secondary ID
Status Completed
Phase Phase 1
First received August 3, 2016
Last updated October 4, 2017
Start date September 2016
Est. completion date November 2016

Study information

Verified date October 2017
Source Santhera Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I open label study is conducted to assess the potential pharmacokinetic interaction of Raxone® with midazolam in healthy male volunteers


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date November 2016
Est. primary completion date November 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

1. Healthy male aged 18 to 55 years.

2. A Body Mass Index (BMI) of 18-30. BMI = Body weight (kg) / Height (m)2.

3. Male subject willing to use an acceptable effective contraceptive measure for the entire duration of study participation.

4. No clinically significant abnormal serum biochemistry, haematology and urine examination values.

5. A negative urinary test for drugs of abuse and alcohol breath screen. A positive alcohol test may be repeated at the discretion of the Investigator.

6. Negative HIV and Hepatitis B and C results.

7. No clinically significant abnormalities in 12 lead electrocardiogram (ECG).

8. No clinically significant abnormalities in blood pressure, pulse or oral temperature.

9. No allergy or sensitivity to midazolam, idebenone or any of their excipients.

10. No current or past medical condition that might significantly affect the pharmacokinetic or pharmacodynamic response to midazolam.

11. Subject must be available to complete the study (including follow-up visit).

12. Subject must satisfy a medical examiner about their fitness to participate in the study.

13. Subject must provide written informed consent to participate in the study.

14. Covered by Health Insurance System and/or in compliance with the recommendations of National Law in force relating to biomedical research.

Exclusion Criteria:

1. A clinically significant history of gastrointestinal disorder likely to influence drug absorption.

2. Use of any medication (prescription or OTC, including health supplements and herbal remedies, except paracetamol, within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose of trial medication.

3. Use of any medication known to induce or inhibit any of the enzymes within the CYP3A system within 28 days of Day 1, or grapefruit within 7 days of Day 1

4. Evidence of renal, hepatic dysfunction, cardiovascular or metabolic dysfunction.

5. History of obstructive sleep apnoea syndrome.

6. History of any significant drug allergy including benzodiazepine.

7. A clinically significant history of drug or alcohol abuse.

8. Inability to communicate well with the Investigator (i.e., language problem, poor mental development or impaired cerebral function).

9. Participation in a clinical trial of a New Chemical Entity within the previous 3 months or of a Marketed Product within the previous 30 days (or 5 times the half-life, whichever is longer).

10. Donation of 450 mL or more blood within the previous 3 months.

11. Smoking or use of tobacco products or substitutes within the previous 6 months, as determined at the Screening visit.

12. Need for administrative or legal supervision.

13. Subject who would receive more than 4500 euros as indemnities for participation in biomedical research within 12 months, including the indemnities for the present study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Raxone (idebenone 150 mg)
Raxone (idebenone 300 mg t.i.d.) on days 3 and days 5 to 10
Midazolam 2,5 mg
Midazolam (2,5 mg single oral dose) on days 1, 3 and 10

Locations

Country Name City State
France Eurofins Optimed Gières

Sponsors (1)

Lead Sponsor Collaborator
Santhera Pharmaceuticals

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area Under the Curve (AUC) from the time of dosing to the time of the last observed concentration (AUC0-t) 13 days
Primary Area Under the Curve (AUC) extrapolated to infinity from dosing time, based on the last observed concentration (AUC0-8) 13 days
Primary Maximum plasma concentration (Cmax) 13 days
Primary Time to Maximum plasma concentration (Cmax) during a dosing interval (tmax) 13 days
Primary Terminal elimination half-life (t1/2) 13 days
Primary Clearance, calculated as dose/AUC0-8 (CL/F) 13 days
Primary Volume of distribution during terminal phase after non-intravenous administration (Vz/F) 13 days
Secondary Area Under the Curve (AUC) from the time of dosing to the time of the last observed concentration (AUC0-t) 13 days
Secondary Area Under the Curve (AUC) extrapolated to infinity from dosing time, based on the last observed concentration (AUC0-8) 13 days
Secondary Maximum plasma concentration (Cmax) 13 days
Secondary Time to Maximum plasma concentration (Cmax) during a dosing interval (tmax) 13 days
Secondary Terminal elimination half-life (t1/2) 13 days
Secondary Clearance (CL) 13 days
Secondary Clearance, calculated as dose/AUC0-8 (CL/F) 13 days
Secondary Volume of distribution (Vz) 13 days
Secondary Volume of distribution during terminal phase after non-intravenous administration (Vz/F) 13 days
See also
  Status Clinical Trial Phase
Completed NCT05692570 - A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers Phase 1
Completed NCT04328766 - Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers Phase 1
Completed NCT03990129 - Pharmacokinetic Interactions of Metamizole (Dipyrone) in Healthy Subjects Phase 1
Completed NCT03985969 - Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin Phase 1
Completed NCT03302845 - A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects Phase 1
Completed NCT01361217 - The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity N/A
Completed NCT06066060 - A DDI Study of JMKX000623 and Metformin Hydrochloride Phase 1
Completed NCT03723395 - A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib Phase 1
Recruiting NCT05789173 - Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK Early Phase 1
Completed NCT04598542 - Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers Phase 1
Recruiting NCT05044962 - Kuwa Free! - Live Free! N/A
Completed NCT04487145 - Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy Phase 4
Completed NCT05108051 - Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir Phase 1
Active, not recruiting NCT04669678 - Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa Phase 4
Completed NCT01991327 - Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males Phase 1
Completed NCT04218513 - Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection Phase 1
Completed NCT05492318 - Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity Phase 1
Completed NCT01309854 - Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects Phase 1
Recruiting NCT05339672 - Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban
Completed NCT05306379 - Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin Phase 1